ArticleBMC endocrine disorders2009
Actos Now for the prevention of diabetes (ACT NOW) study.
Article in BMC endocrine disorders, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of a Quadruple Therapy on Pancreatic Islet Function, Insulin Resistance and Cardiovascular Function in Patients With Mixed Prediabetes and Obesity: Randomized Clinical Trial
Actos Now for Prevention of Diabetes (ACT NOW)
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2020 · on this mapPooled it
- Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle.Scientific reports · 2021Trial
- Rationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in Prediabetes.Journal of diabetes research · 2017Trial
- Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance.Age (Dordrecht, Netherlands) · 2016Trial
- Effect of Acarbose on Long-Term Prognosis in Acute Coronary Syndromes Patients with Newly Diagnosed Impaired Glucose Tolerance.Journal of diabetes research · 2016Trial
- A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study.The Journal of clinical endocrinology and metabolism · 2015Trial
- Trial
- Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors.Arteriosclerosis, thrombosis, and vascular biology · 2013Trial
- Effectiveness of internet-based management in newly diagnosed young adults with type 2 diabetes: a prospective comparative study.Endocrine connections · 2025Article
- Obesity in Prediabetic Patients: Management of Metabolic Complications and Strategies for Prevention of Overt Diabetes.Endocrine, metabolic & immune disorders drug targets · 2025Review
- Prediabetes and Cardiometabolic Risk: The Need for Improved Diagnostic Strategies and Treatment to Prevent Diabetes and Cardiovascular Disease.Biomedicines · 2024Review
- Modifiable predictors of type 2 diabetes mellitus and roles of insulin resistance and β-cell function over a 6-year study and 30-year follow-up.Journal of endocrinological investigation · 2023Article
- Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies.Diabetology international · 2019Article
- Making Strides in Type 2 Diabetes Prevention.Diabetes spectrum : a publication of the American Diabetes Association · 2018Article
- Machine learning to predict rapid progression of carotid atherosclerosis in patients with impaired glucose tolerance.EURASIP journal on bioinformatics & systems biology · 2016Article
- Prevalence of unrecognized diabetes, prediabetes and metabolic syndrome in patients undergoing elective percutaneous coronary intervention.Diabetes/metabolism research and reviews · 2015Article
- Article
- Efficacy and Safety of Canagliflozin as Add-On Therapy to Metformin in Type 2 Diabetes.Clinical diabetes : a publication of the American Diabetes Association · 2014Article
- Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus.Therapeutics and clinical risk management · 2014Review
- Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk.Diabetes care · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImpaired glucose tolerance (IGT) is a prediabetic state. If IGT can be prevented from progressing to overt diabetes, hyperglycemia-related complications can be avoided. The purpose of the present study was to examine whether pioglitazone (ACTOS) can prevent progression of IGT to type 2 diabetes mellitus (T2DM) in a prospective randomized, double blind, placebo controlled trial. METHODS/
design602 IGT subjects were identified with OGTT (2-hour plasma glucose = 140-199 mg/dl). In addition, IGT subjects were required to have FPG = 95-125 mg/dl and at least one other high risk characteristic. Prior to randomization all subjects had measurement of ankle-arm blood pressure, systolic/diastolic blood pressure, HbA1C, lipid profile and a subset had frequently sampled intravenous glucose tolerance test (FSIVGTT), DEXA, and ultrasound determination of carotid intima-media thickness (IMT). Following this, subjects were randomized to receive pioglitazone (45 mg/day) or placebo, and returned every 2-3 months for FPG determination and annually for OGTT. Repeat carotid IMT measurement was performed at 18 months and study end. Recruitment took place over 24 months, and subjects were followed for an additional 24 months. At study end (48 months) or at time of diagnosis of diabetes the OGTT, FSIVGTT, DEXA, carotid IMT, and all other measurements were repeated.Primary endpoint is conversion of IGT to T2DM based upon FPG >or= 126 or 2-hour PG >or= 200 mg/dl. Secondary endpoints include whether pioglitazone can: (i) improve glycemic control (ii) enhance insulin sensitivity, (iii) augment beta cell function, (iv) improve risk factors for cardiovascular disease, (v) cause regression/slow progression of carotid IMT, (vi) revert newly diagnosed diabetes to normal glucose tolerance.
conclusionACT NOW is designed to determine if pioglitazone can prevent/delay progression to diabetes in high risk IGT subjects, and to define the mechanisms (improved insulin sensitivity and/or enhanced beta cell function) via which pioglitazone exerts its beneficial effect on glucose metabolism to prevent/delay onset of T2DM.
trial registrationclinical trials.gov identifier: NCT00220961.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.